Therapeutic effects of Guanabenz treatment in vanishing white matter

Abstract

The invention relates to Guanabenz or an analogue thereof for use in the treatment and to methods of treatment of a subject that has vanishing white matter (VWM), comprising administering the compound Guanabenz or an analogue thereof to the subject in need thereof. Also provided are methods with which the success of a medical intervention in a subject with VWM can be determined. Such methods comprise quantifying the translocation of Bergmann glia into the molecular layer in the cerebellum in a suitable sample of the subject. The sample is typically a post mortem sample.

Claims

1. A method of treatment of a human subject that has vanishing white matter, the method comprising administering the compound guanabenz to the human subject in need thereof.

2. The method of claim 1, wherein the compound is administered to the human subject orally in the form of a pill or a capsule.

3. The method of claim 1, wherein the dosage is 50 ug/kg/day-1 mg/kg/day based on the weight of the human subject to be treated.

4. The method of claim 1, wherein the dosage is 0.1-1 mg/kg/day based on the weight of the human subject to be treated.

5. The method of claim 1, wherein the dosage is 0.125-0.5 mg/kg/day based on the weight of the human subject to be treated.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1. Bergmann glia in VWM mice express markers of immaturity. (A) Bergmann glia of the cerebellum of 7-month-old VWM (2b5.sup.ho) mice are immunopositive for the radial glia marker RC2, and often show an abnormal morphology with short processes that are retracted from the pial membrane. (B) nestin expression in Bergmann glia is observed in 5- and 7-month-old 2b5.sup.ho mice, but not in 2-month-old 2b5.sup.ho mice or wild type (WT) mice. The green staining that is observed in the picture of the 2-month-old 2b5.sup.ho mice and the 2- and 5-month-old WT mice is non-specific staining of blood vessels, that does not co-localize with GFAP staining. Large, closed arrows indicate regions with double staining; small, open arrows indicate non-specific nestin staining. ML=molecular layer, PCL=Purkinje cell layer, GCL=granule cell layer. Scale bar A=25 μm; scale bar B=50 μm.

(2) FIG. 2. Bergmann glia translocate into the molecular layer in VWM mice. (A) Immunostaining for S1000ß shows Bergmann glia cell bodies and processes in 7-month-old WT and 2-, 5- and 7-month-old 2b5.sup.ho mice. In WT mice the majority of the Bergmann glia cell bodies is located in the Purkinje cell layer (see arrows). Bergmann glia in the 5- and 7-month-old 2b5.sup.ho mice have cell bodies translocated to the molecular layer (Large arrows; normally localized cell bodies are indicated by small arrows). (B) Data points show the ratio between S100ß-positive cell bodies in the molecular layer and the total number of S100ß-positive cell bodies. Each data point represents an individual mice, with solid data points indicating mean±SEM. *=p<0.05; **=p<0.01. Scale bar=50 μm; BG=Bergmann glia.

(3) FIG. 3. All VWM patients with different disease severities show Bergmann glia translocation. (A-B) Immunostaining for S100 shows a significantly higher number of translocated Bergmann glia in tissue of VWM patients with severe, classic and mild forms than in control tissue. Large arrows indicate translocated Bergmann glia; normally localized cell bodies are indicated by small arrows. (C) A linear trend line shows a negative correlation with age for VWM patients, although the trend is not significant. (B) Each data point represents an individual patient or control, with solid data points indicating mean±SEM. (C) Each data point represents an individual patient or control, with a linear trend line showing the correlation between age and Bergmann glia translocation. **=p<0.01. Scale bar=50 μm. Ctrl=Control, BG=Bergmann glia

(4) FIG. 4. Guanabenz treatment improves Bergmann glia pathology. (A-B) The number of nestin-GFAP double positive cells is decreased in the corpus callosum of 3 out of 4 Guanabenz-treated animals compared to saline-treated animals. (C-D) The number of translocated Bergmann glia nuclei is significantly decreased after Guanabenz treatment. GFAP staining also shows a normalization of the Bergmann glia morphology in Guanabenz treated animals (see inset). (A,C) Data points represent individual mice, with solid data points indicating mean±SEM. animals. Scalebar=50 μm; *=p<0.05. BG=Bergmann glia, GBZ=Guanabenz.

(5) FIG. 5. Oligodendrocyte and myelin pathology is improved in the cerebellum after Guanabenz treatment. (A) The number of Plp-expressing cells in the cerebellum of 2b5.sup.ho mice is significantly lower than in the cerebellum of WT mice. After Guanabenz treatment an increase in the number of Plp-expressing cells is observed in both the corpus callosum (B) and in the cerebellum (B-C), but not significantly. (D-E) Western blot analysis of protein lysates shows increased amounts of MOG protein in the forebrain and cerebellum of Guanabenz treated animals compared to saline-treated animals. (F) The amount of MBP protein is increased in the cerebellum but not in the forebrain of Guanabenz treated animals. Correlation analysis shows a significant inverse correlation between the number of nestin-positive and Plp-positive cells in the corpus callosum (G), but the correlation between translocated Bergmann glia and the Plp-positive cells in the cerebellum does not reach the level of significance (H). (A-B; E-F) Data points represent individual mice, with solid data point indicating mean±SEM. (G-H) Data points represent individual mice, with a linear trendline showing the correlation between variables. *=p<0.05. CC=corpus callosum, CB=Cerebellum, FB=forebrain, GBZ=Guanabenz.

(6) FIG. 6. Quantification of Bergmann glia cell body translocation. Bergmann glia translocation is quantified on 100× magnification pictures of S100ß staining. Images are opened in Image J, and with the segmented line tool an line through the Purkinje cell layer is drawn (A). With the “line to area” and “enlarge” tool, the line is expanded to a band of 0.406 cm (mice) or 0.635 cm (human) (B). The S100ß-positive nuclei inside the band are considered correctly localized, and the S100ß-positive nuclei in the molecular layer outside the band are considered translocalized (C). (D) shows an example of the 0.635 cm band on a picture of a human tissue section stained with S100.

(7) FIG. 7. Original western blots. (A) Complete western blot probed with MOG antibody, (B) shows the protein scan of the same blot used for quantification. (C) Complete western blot probed with MBP antibody, (D) shows the protein scan of the same blot used for quantification.

(8) FIG. 8. Purkinje cells do not show abnormalities in VWM. Staining for Cyclin D1 shows that Bergmann glia with an abnormal morphology are not Cyclin D1 positive (A) suggesting that they are not proliferating. The amount of Purkinje cells (B) is similar in 7-month-old WT and 2b5ho mice, and staining for Calbindin shows no abnormalities in Purkinje cells of 2b5ho mice (C). (B) Data points represent individual mice, with solid data points indicating mean±SEM. animals. Scalebar=25 μm.

(9) FIG. 9. Stress-induced ATF4 expression is significantly increased by Guanabenz (Gb) and Sephin1 (S1) in human astroglioma cell line (U373). ATF4 expression was assessed with a luciferase reporter construct under regulation of the murine Atf4 promoter and 5′ non-coding region. Cells were transfected as described [36]. The ISR was induced by administration of 3 nM thapsigargin (TG) to the cell culture medium. 15 μM ISR modulators Gb, Sephin1 (S1, also a GADD34 inhibitor, but without α2 adrenergic effect) or ISRIB (I, an activator of eIF2B) were added simultaneously with or without TG for 16 hours (e.g. −TG/+Gb and +TG/+Gb). Guanfacin (Gf), an a2 adrenergic receptor agonist without reported GADD34 modulating activity, was included in parallel as negative control. Cell stress modulators Gb and S1 increase ATF4 expression in the presence of TG. This effect was not observed with Gf and was opposite in ISRIB. Statistical analyses were performed for individual compounds with a paired t-test (*, p<0.05, **, p<0.01).

(10) FIG. 10. Guanabenz transiently reduces eIF2a phosphorylation in brain tissue from control and 2b5ho mutant mice, which is accompanied by a reduced ISR mRNA marker expression in 2b5ho mice. Adult gender-matched mice were injected intraperitoneally with saline or Gb (10 mg/kg). eIF2a phosphorylation was measured with Western blot and mRNA levels with qPCR in post-mortem brain tissue collected 4 or 24 hours (h) after injection. Statistical analysis was performed with two-way ANOVA (*, p<0.05, **, p<0.01, ***, p<0.001).

EXAMPLES

Example 1

(11) Materials and Methods

(12) Animals

(13) Tissue sections of 11 WT and 10 2b5.sup.ho (carrying a homozygous Arg191His mutation in the Eif2b5 gene [7]) animals of 2, 5 or 7 months of age were collected after intracardiac perfusion with 4% paraformaldehyde (PFA). The brains were postfixed in 4% PFA for 1-2 days, after which half of the brain was embedded in paraffin and the other half was incubated overnight in 30% sucrose and snapfrozen in optimum cutting temperature compound (Sakura). The brain of one 3-month-old shiverer mice (kindly provided by Prof. Dr. David Rowitch, UCSF, San Francisco, Calif., USA) was processed in a similar way. To test the effect of Guanabenz, 11 female 2b5.sup.ho littermates were injected with saline (n=5) or Guanabenz (10 mg/kg; n=6) i.p. every week from 2 months until 10 months of age. Animals were randomly assigned to the Guanabenz or saline group, and single animals were taken as experimental units. At 11 months of age all mice were sacrificed and the brains were used for analysis. The brains of 3 saline- and 4 Guanabenz-injected animals were perfused as described and used for immunostaining and in situ hybridization. The brains of 2 saline- and 2 Guanabenz-injected animals were snapfrozen in liquid nitrogen and used for western blot analysis. No animals were excluded from any analysis. All animals were weaned at P21 and had ad libitum access to food pellets and water. Mice were considered “symptomatic” when they show motor signs like ataxia, which started around 5 months of age.

(14) Patients

(15) Tissue of 10 genetically proven VWM patients and 4 non-neurologic controls was collected at autopsy. Human tissue was processed as previously described [6]. Patient characteristics including mutations, age at disease onset and age at death are summarized in Table S1. Patients were classified as “mild”, “classic” and “severe” based on age of onset and disease duration.

(16) Immunostaining

(17) Mouse tissue was processed for immunostaining as previously described [7]. Shortly, snapfrozen brains were cut in 12 μm thick sections. Sections were pretreated with citrate buffer (pH 6.0) at 90° C. for 10 min. Blocking buffer (phosphate-buffered saline (PBS)+5% normal goat serum+0.3% Triton X-100+0.1% bovine serum albumin) was used for 1 hour blocking and for antibody incubation. See Table 1 for a list of primary antibodies. Secondary antibodies were Goat-anti-mouse Alexa Fluor 488 and Goat-anti-rabbit Alexa Fluor 594. After staining, slides were incubated with 4′,6-diamidino-2-fenylindool (DAPI) (Sigma; 1:1000) for 2 min and embedded with Fluoromount G. Human tissue was formalin-fixed, paraffin-embedded and cut in 4 μm thick sections. Sections were deparaffinized and antigen retrieval was performed in Tris/ethylenediaminetetraacetic acid (EDTA) buffer (pH 9) before primary antibody incubation. Immunoreactivity was detected with 3,3′-diaminobenzidine as chromogen and counterstained with hematoxylin. Stainings were analyzed with a LeicaDM6000B microscope (Leica Microsystems). Omitting primary antibodies did not yield any specific staining. Pictures were acquired as TIFF files and optimized for brightness and contrast using Adobe Photoshop 8.0 (Adobe Systems).

(18) Analysis of Bergmann Glia Translocation

(19) Bergmann glia pathology was analyzed in S100ß-stained sections. Per animal 3-6 pictures at 100× magnification of the cerebellar cortex were taken, all including the molecular layer, Purkinje cell layer and granular layer. Analysis was done with Image J software (imagej.nih.gov/ij/); the segmented line tool was used to draw a line through the middle of the Purkinje cell layer. Around this line, a band of 0.406 cm (mouse tissue) or 0.635 cm (human tissue) was made by using the “line to area” and “enlarge” tools (Figure S1). The band sizes were chosen so that the Purkinje cell bodies were completely located inside the band together with the majority of Bergmann glia cell bodies in control tissue. All the S100-positive cell bodies inside this band were counted and considered correctly localized. The S100ß-positive cell bodies located outside the band in the molecular layer were counted and considered as translocated Bergmann glia. The amount of translocated cell bodies was expressed as a ratio to the total number of S100ß-positive cell bodies counted.

(20) Nestin Cell Count

(21) Astrocytes double-positive for nestin and GFAP were counted in the splenium and rostrum of the corpus callosum, on 100× magnification pictures. Total cell number was determined by counting the DAPI-positive nuclei. For each animal, at least 3 slices were stained and counted. The ratio of nestin/DAPI positive cells was used for further analysis.

(22) Analysis of Purkinje Cell Number

(23) The number of Purkinje cells in the cerebellum was assessed with staining for Calbindin on 100× magnification pictures. For each animal, at least 6 pictures of different areas of the cerebellum were taken, all including the Purkinje cell layer. The number of Purkinje cells in each picture was counted and corrected for the length of the Purkinje cell layer, which was measured by drawing a line through the Purkinje cell layer using the “segmented line” tool in ImageJ and measuring the length of the line with the “Measure” option.

(24) In Situ Hybridization

(25) In situ hybridization targeting proteolipid protein (Plp) mRNA was performed on PFA-fixed snapfrozen tissue as previously described [7, 25]. Plp probe was incubated overnight in hybridization buffer, targeted with anti-digoxygenin (1:2000, Roche) and developed with BM purple (Roche). Nuclei were counterstained with 0.5% methylgreen. The number of Plp-positive cells was analyzed in the rostrum and splenium of the corpus callosum, and in the white matter of the cerebellum. For each area 3 different pictures were taken with a 100× objective lens and cells were counted in a 100×200 μm square.

(26) Western Blot

(27) Half of the forebrain and the whole cerebellum of 2 saline- and 2 Guanabenz-treated animals were separately used for western blot analysis. Forebrains were lysed in lysis buffer (50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 2.5 mM ethylene glycol-bis(β-aminoethyl-ether)-N,N,N′,N′-tetraacetic acid, 0.1% Triton-X100, 10% glycerol, 1 mM dithiothreitol) supplemented with protease inhibitor cocktail (ThermoFisher Scientific) using a dounce tissue grinder (Sigma-Aldrich). Samples were incubated on ice for 20 min and centrifuged 15 min at 13.000 rpm. Supernatants were collected and protein concentrations were measured with a Bradford assay. Samples (60 μgr of total protein) were separated on a 12% SDS-PAGE gel and transferred onto an activated polyvinylidene fluoride-membrane. After the transfer blots were scanned on a BioRad scanner to measure total protein content (Figure S2). Blots are blocked for 1 hour with 5% milk in PBS and incubated overnight in primary antibody diluted in 2.5% milk in PBS at 4° C. The next day, blots were blocked for 10 min in 5% milk and incubated in secondary antibody diluted in 2.5% milk in PBS at room temperature for 1 hour. Secondary antibodies were raised against mouse or rabbit and conjugated with horseradish peroxidase. Blots were developed with SuperSignal™ West Femto Maximum Sensitivity Substrate (ThermoFisher Scientific) and measured in an Odyssey® Fc Imaging System (LI-COR Inc). Intensity of bands was quantified with ImageJ software and corrected for total amount of protein. Total protein content as a loading control is more sensitive than a single-protein loading control and less susceptible for variation due to treatment [26, 27].

(28) Statistical Analyses

(29) Data of nestin cell counts, Bergmann glia localization and Plp cell counts was analyzed with SPSS software package (IBM SPSS Statistics 20.0). Data was analyzed with an independent samples t-test if the data met the assumptions for a parametric test and if the distribution did not deviate significantly from normal as determined by a Shapiro-Wilk test. For data that did not meet parametric assumptions a Mann-Whitney U test was performed. For trend analysis a one-way ANOVA with polynomial contrasts was used. Pearson's correlation coefficient r was used as a measure for the effect size (r>0.5 was considered a large effect) and to analyze the correlation between different variables.

(30) Results

(31) Bergmann Glia in Late Symptomatic VWM Mice Express Radial Glia Marker RC2 and Neural Stem Cell Marker Nestin

(32) Astrocytes in postmortem tissue of VWM patients and in the forebrain of adult 2b5.sup.ho mice express markers of immaturity [7]. In the corpus callosum, astroytic abnormalities can already be observed in the first postnatal weeks in the 2b5.sup.ho mice, while clinical symptoms as ataxia only appear from 5 months of age onwards. So far it is unclear whether the Bergmann glia show other markers of immaturity besides GFAPδ and at what age these become apparent. Therefore we performed immunohistochemistry for the radial glia marker RC2 and neural stem cell marker nestin at the postmortem cerebellum of 2b5.sup.ho mice of different ages. The RC2 antibody recognizes a variant of Nestin that is under normal circumstances only expressed in radial glial. Bergmann glia in 7-month-old 2b5.sup.ho animals showed immunopositivity for RC2, which was undetectable in adult age-matched WT mice and in 2- and 5-month-old 2b5.sup.ho animals (FIG. 1A). RC2 staining was present in Bergmann glia that were mostly also bright GFAP-positive, had a translocated soma into the molecular layer and showed an abnormal morphology with short, thick processes that were retracted from the pial membrane (FIG. 1A). Nestin expression was present in Bergmann glia of 5- and 7-month-old 2b5.sup.ho animals, but not in 2-month-old 2b5.sup.ho animals and WT animals of any age (FIG. 1B). The expression of nestin was more prominent in Bergmann glia with an abnormal morphology, that were previously shown to have an increased expression of GFAPδ at similar ages.

(33) Alongside immaturity, the proliferation status of Bergmann glia was determined. CyclinD1 is a protein that is abundant in the G1 and the G1/S phase transition during the cell cycle, and therefore labels proliferating cells. Staining of 7-month-old 2b5.sup.ho and WT animals with CyclinD1 and GFAP showed that the translocated Bergmann glia with abnormal morphology were not CyclinD1 positive (Figure S3A). So Bergmann glia in 7-month-old 2b5.sup.ho mice express markers of immaturity but do not express the proliferative cell marker Cyclin D1 at 7 months of age. Immunocytochemistry for Calbindin in 7-month-old 2b5.sup.ho and WT animals showed no abnormalities in amounts or morphology of Purkinje cells in the 2b5.sup.ho mice ([7]; Figure S3B-C).

(34) Bergmann Glia Translocation is a Quantitative Measure of VWM Pathology

(35) While in normal conditions the nuclei of Bergmann glia are located in the Purkinje cell layer, symptomatic VWM mice and patients show translocation of Bergmann glia nuclei to the molecular layer, worse so in mice with more severe disease [7]. To use Bergmann glia translocation as a biological read-out for treatment effectiveness, we developed a method that allowed quantitative assessment of Bergmann glia pathology. Cryo-preserved sections of 2-, 5- and 7-month-old WT and 2b5.sup.ho mice were immunostained for S100ß, which visualizes both soma and processes of Bergmann glia. The number of S100ß-positive cell bodies inside and outside the Purkinje cell layer was counted. At 5 months (p=0.046) and 7 months (p=0.002) of age, 2b5.sup.ho mice showed a significantly increased number of translocated Bergmann glial cell bodies (FIG. 2A-B, Table S2). The linear trend of the Bergmann glia translocation from 2-month-old to 7-month-old 2b5.sup.ho mice was significant (p=0.001, r=0.94), indicating that Bergmann glia translocation becomes apparent at symptomatic disease stages of VWM and worsens over the disease course.

(36) Analysis of brain tissue of 10 VWM patients with different disease severities showed that all patients have increased Bergmann glia translocation compared to controls (FIG. 3A-B, Table S2). Between patients there was quite some variance in the number of translocated Bergmann glia, and a trend towards a lower number of translocated Bergmann glia in the older (milder) VWM patients was observed (FIG. 3C), although non-significant. As no Bergmann glia translocation was observed in the brain of the shiverer mouse (Table S2), this disease marker is not a general feature of brain white matter abnormalities.

(37) Guanabenz Treatment Rescues Bergmann Glia Translocation

(38) To analyze whether Guanabenz treatment improves VWM pathology, 2b5.sup.ho mice were treated with 10 mg/ml i.p. Guanabenz between 2- and 10 months of age. At 11 months of age, Guanabenz- and saline-treated animals were sacrificed and first analyzed for the pre-symptomatic disease marker nestin. The number of nestin-positive cells in the corpus callosum decreased in all but one Guanabenz-treated animal compared to saline-treated animals (FIG. 4A-B, Table S3), but the average decrease of 27% failed to reach significance (p=0.289). To test whether Guanabenz treatment rescues biomarkers of the symptomatic disease state, we analyzed Bergman glia cell localization. We found that the Guanabenz treatment significantly decreased the number of translocated Bergmann glia cell bodies by 30% and reached the numbers found in untreated WT animals. (p=0.032; FIG. 4C-D, Table S2). This was accompanied by a decreased GFAP expression and a normalization of Bergmann glia morphology (FIG. 4D). These data indicate that Guanabenz treatment improves VWM pathology, and rescues Bergman glia translocation when started at early-symptomatic disease stages.

(39) Guanabenz Treatment Improves Myelin Pathology in the Cerebellum of VWM Mice

(40) The 2b5.sup.ho mice show oligodendrocyte abnormalities and myelin pathology [7], which was previously quantified in the corpus callosum with in situ hybridization for Plp, a marker for mature oligodendrocytes. To validate myelin abnormalities in the cerebellum, we now analyzed Plp expression in the cerebellar white matter of 7-month-old 2b5.sup.ho and WT mice. The number of Plp-expressing cells in the cerebellum of 2b5.sup.ho mice was significantly lower than in the cerebellum of WT mice (FIG. 5A, Table S4). After Guanabenz treatment, the number of Plp-expressing cells was slightly increased in the forebrain and cerebellum, though not significantly (FIG. 5B-C, Table S4). The increase was higher in the cerebellum than in the corpus callosum.

(41) To analyze the effects of Guanabenz treatment on myelin pathology in the cerebellum of 2b5.sup.ho animals, we performed Western blot analysis for the mature myelin proteins myelin basic protein (MBP) and myelin-oligodendrocyte glycoprotein (MOG). Both were increased in the cerebellum of 2b5.sup.ho animals after Guanabenz treatment (FIG. 5D-F, Table S5, Figure S2). In the forebrain only the amount of MOG protein was increased. So Guanabenz-treated 2b5.sup.ho animals showed improvement of oligodendrocyte and myelin pathology, which was more prominent in the cerebellum than in the forebrain.

(42) Markers of Astrocyte and Oligodendrocyte Pathology in Different Brain Regions Correlate with Disease Severity in Different Temporal Patterns

(43) Interestingly, the Guanabenz-treated animal that showed the highest number of nestin-positive cells also showed the lowest number of Plp-expressing cells in the corpus callosum. This finding prompted a correlation analysis between the different markers. In the corpus callosum, we confirmed a significant inverse correlation between the number of nestin-positive cells and the Plp-positive cells (r=−0.811, p=0.027, FIG. 5G, Table S6). In the cerebellum, we found an inverse correlation between the number of Plp-positive cells in the cerebellar white matter and the ratio of translocated Bergmann glia, but this correlation was not significant (r=−0.723, p=0.66; FIG. 5H, Table S6). We looked at the correlations between measurements in different brain areas and found no significant correlation between measures for the corpus callosum and the cerebellum (Table S6). So the measurements of different brain areas, which all correlate with disease severity, lack significant correlations between each other suggesting some degree of independence between the pathology in those areas.

(44) Discussion

(45) Different astrocytic cell populations are affected in the brain of VWM patients, which is recapitulated in recently developed VWM mouse models. Cerebellar Bergmann glia in both VWM patients and symptomatic mice show upregulated expression of GFAPδ and lost radial morphology. One of the clearest signs of VWM pathology in the cerebellum is translocation of Bergmann glia into the molecular layer [7]. In the current experiments we used the 2b5.sup.ho VWM mouse model to determine Bergmann glia pathology in more detail.

(46) Bergmann glia have important functions in the development of cerebellar cortical architecture and in information processing in the molecular layer of the adult cerebellar cortex [28]. Our analysis of the Bergmann glia showed that staining for the radial glia marker RC2 is present in symptomatic VWM mice. Since RC2 immunopositivity is normally not present in the adult brain [29], these results indicate that Bergman glia like other glia cell populations in the VWM brain have an immature phenotype. While Bergmann glia are important for proper layering in the cerebellum, we found no changes in the cerebellar architecture of the cortical cell layers [7]. Quantification of Bergmann glia translocation at different disease states showed that the number of translocated Bergmann glia is significantly increased at 5 and 7 months of age compared to control mice, when VWM mice start to show clinical symptoms. In younger animals Bergmann glia have normal localization and morphology and do not express early markers like nestin and RC2. By contrast, white matter astrocytes in the corpus callosum of VWM already show nestin overexpression at P14 [7]. In VWM patient tissue only the disease end-stage can be assessed, and it is not possible to track the Bergmann glia translocation within one patient over time. All patients showed Bergmann glia translocation. VWM disease severity and age of onset (and death) are inversely correlated. In the oldest VWM patients, with a mild disease variant, the number of translocated Bergmann glia was lower than in the younger patients. This suggests a correlation between disease severity and Bergmann glia translocation, although this needs to be confirmed in a larger group of patients. Abnormalities of Bergmann glia translocation were not observed in the myelin deficient shiverer mice, which lacks astrocytic abnormalities. This suggests that Bergmann glia translocation is not a general consequence of white matter abnormalities.

(47) Why Bergmann glia in VWM translocate into the molecular layer is not known. Since Bergmann glia have tight connections with Purkinje cells [28], this phenomenon could be linked to Purkinje cell pathology. However, no loss of Purkinje cells is observed in VWM mice. Upregulation of Nestin and GFAP in Bergmann glia is further seen upon e.g. traumatic injury [30, 31] and in Creutzfeldt-Jacobs disease [32]. While upregulation of Nestin and GFAP is a known feature of reactive astrocytes, reactive Bergmann glia do not form a glial scar like other astrocytes. Additionally, they keep their normal position and, when Bergmann glia processes are damaged, their radial glia like morphology is recovered over time. Therefore, the Bergmann glia translocation observed in VWM does not correspond to “normal” reactive gliosis of Bergmann glia. So, other mechanisms must underlie Bergmann glia translocation in VWM. Maturation and fiber formation of Bergmann glia is tightly regulated during development and requires active maintenance later in life [28]. For proper functioning of the Bergmann glia, their processes need correct anchoring to the basement membrane on the cerebellar surface. Dysregulation of proteins and pathways involved in these assembles, like ß1-integrin, α-dystroglycan, Notch, FGF9 and the P13K/AKT pathway (see [28] for extensive review), will lead to loss of Bergmann glia morphology, translocation of Bergmann glia cell bodies to the molecular layer and consequently disrupted cerebellar layering. Glia-specific knockdown of components of the Notch [33] and Wnt [34] signaling pathways can lead to abnormal Bergmann glia morphology and localization in later postnatal stages, without effecting cerebellar layering. Interestingly, mice with a knockdown of adenomatous polyposis coli in GFAP-expressing cells show Bergmann glia translocation to the molecular layer like VWM mice [34]. Further research is needed whether one of these mechanisms is involved in the translocation of Bergmann glia in VWM.

(48) Astrocyte dysfunction is thought to underlie the myelin deficits found in VWM. Here we show that Guanabenz treatment rescues Bergmann glia translocation in VWM mice. Interestingly cerebella of the Guanabenz-treated VWM mice also showed improvements in myelin content. In the corpus callosum the astrocyte pathology was not significantly improved with Guanabenz treatment, and the increase in number of mature oligodendrocytes and myelin content was smaller than in the cerebellum.

(49) To address effectiveness of treatment options, disease markers that fit the treatment window should be evaluated. An increased number of nestin-positive astrocytes in the corpus callosum of VWM mice is already observed at P14, during pre-symptomatic disease stages. Since Guanabenz injections were only started at 2 months of age, it is likely that Guanabenz treatment was initiated too late to rescue disease makers of pre-symptomatic disease stages. Indeed, the numbers of Nestin-positive cells in the corpus callosum were not significantly reduced, although 3 out of 4 Guanabenz treated animals showed a decreased number. Although increased nestin cell counts in the corpus callosum reliably marks VWM from the pre-symptomatic stage onwards, its sensitivity to treatment needs further tests to validate it as a VWM disease marker sensitive to therapy. By contrast, Bergmann glia abnormalities are only observed from 5 months of age onwards, increase with disease progression and clearly improve with treatment. As the Bergmann glia abnormalities start at the same time as clinical signs like ataxia, Bergmann glia translocation cannot be used as a predictive marker for VWM in pre-symptomatic disease stages. However, it is sensitive for treatment and can therefore be used in studies testing new treatment options.

(50) There was a significant inverse correlation between the number of nestin-positive astrocytes and the number of Plp-positive oligodendrocytes in the corpus callosum of 2b5.sup.ho mice. This suggests that decreased astrocyte dysfunction correlates with improved myelin in the corpus callosum, either through a causative relation or by an underlying mechanism affecting both astroytes and oligodendrocytes equally. Absence of direct contact between Bergmann glia in the Purkinje cell layer and the Plp-positive oligodendrocytes in the white matter of the cerebellum could explain the less strong correlation between these populations. We found no significant correlation between measurements of the cerebellum and the corpus callosum. So different parameters of VWM pathology are only correlated within the same brain region. All individual markers reliably predict and correlate with the disease state, but in a different temporal pattern. This suggests that the measurements in the different regions are independent from each other, while all correlate with disease severity. Therefore using all three measures together gives a more complete picture of different aspects of VWM pathology.

(51) Guanabenz-treated animals only showed significant improvements for some parameters, which is possibly explained by the choice of dose and timing of administration. A dose of 4-16 mg/kg Guanabenz is sufficient to achieve brain levels capable of modulating the endoplasmic reticulum stress response [19]. However daily injections are more effective than weekly injections [15], possibly because the effect of Guanabenz on p-eIF2 is only short-lived [19]. Taking these studies into account, increased improvements using daily administration of a lower dose of Guanabenz are expected. Additionally, other compounds that regulate eIF2 phosphorylation should be tested, as Guanabenz acts as a2 adrenergic receptor agonist mainly. For example, Das et al. [35] recently have synthesized Sephin1, which lacks a2-adrenergic activity, but sustains p-eIF2 under ER stress conditions and is able to cross the blood-brain-barrier. Sephin1 treatment improved the phenotype of mice modeling Charcot-Marie-Tooth disease and amyotrophic lateral sclerosis. No adverse side effects after acute or chronic treatment of Sephin1 in mice were observed. The Guanabenz treatment regimen used in the present invention shows improved treatment protocols are possible with Guanabenz itself or other compounds that can regulate eIF2 phosphorylation.

(52) To conclude, we show that Bergmann glia translocation is a quantifiable disease marker for symptomatic disease stages of VWM and provides a sensitive measure for disease progression and treatment effectiveness that can be used in mice. Although the Guanabenz treatment regimen chosen only gave significant improvements for some parameters of VWM pathology, the present invention shows that compounds acting on p-eIF2 have good prospects for future treatment strategies for VWM, involving a more intensive treatment schedule or a multimodal treatment approach together with e.g. cell or gene therapy. We are currently preparing a clinical trial to assess the effects of Guanabenz on disease progression in VWM patients.

Example 2

(53) Cellular stresses increase the level of phosphorylated eIF2a, which sequesters eIF2B in an inactive form. This pathway is known as the integrated stress response (ISR). As a consequence of decreased eIF2B activity, the overall protein synthesis rate is inhibited, but increased for specific mRNAs. The mRNA encoding ATF4 is such an mRNA: the synthesis of the ATF4 protein increases during the ISR. ATF4 is a transcription factor that induces expression of various genes that are important for protective cellular responses and for negative feedback regulation. ATF4-regulated genes include DDIT3 (encoding CHOP), TRIB3 and GADD34. As a consequence of this combined expression, cells can cope with and counteract cell stress and return to their normal state when the stress has been relieved, or die if the stress was too longstanding or severe. VWM is caused by mutations in eIF2B subunits, decreasing its activity. Consequently, ATF4 and its transcriptome are always activated.

(54) The a2 adrenergic receptor agonist Guanabenz (Gb) has been reported to also target GADD34 and thereby impact on a negative feedback loop of the ISR [16]. GADD34 promotes dephosphorylation of eIF2P. Gb is thought to inhibit GADD34, it is thereby though to increase and prolong eIF2a phosphorylation and consequently increases production of ATF4 and its regulated transcriptome. We tested the effect of Gb on ATF4 production in U373 cell lines using a stress-sensitive transfection assay. Transfections were performed with the pNL1.1-mATF4 reporter construct, in which expression of the reporter gene is controlled by ISR-responsive sequences. Expression from the reporter construct was measured 2 days after transfection with a commercially available chemiluminescent assay [36] and can be directly interpreted as a measure for ATF4 expression.

(55) ATF4 expression was investigated in the absence or presence of ISR activation. The ISR was induced by addition of thapsigargin to the culture medium 16 hours before cells were harvested and ATF4 synthesis was measured. Gb was added together with thapsigargin to the culture medium to test the effect of Gb on ATF4 expression. In this experiment we included additional compounds as controls in parallel cultures: Sephin1 (another compound with GADD34-inhibiting capacity but without a2 adrenergic receptor agonism) and Guanfacine (an a2 adrenergic receptor agonist without GADD34 inhibiting capacity). The eIF2B-enhancing compound ISRIB was included as positive control for ATF4-regulation. This compound reduces ATF4 expression [37; 38]. The results are shown in FIG. 9. The compounds behaved as expected: Gb and Sephin1 increased and ISRIB reduced ATF4 expression under stress. The effect of Guanfacine on ATF4 expression was small, variable and not statistically significant. Sephin1 seemed to increase ATF4 expression more effectively than Gb, but the effect did not reach statistical significance.

(56) Considering its effect of increasing ATF4 expression, one would expect Gb to increase VWM pathology and disease severity. However, unexpectedly, an ameliorating effect of Gb on VWM neuropathology has recently been demonstrated in VWM (2b5ho) mice [39]. As (unpublished) part of this study, we investigated the effect of Gb on the expression of ATF4 and its regulated transcriptome in mice. The results were counterintuitive and difficult to explain. In short, we injected one dose of 10 mg/kg Gb intraperitoneally into four wildtype (wt) and four 2b5ho mice. Saline-injected wt and 2b5ho mice were used as negative controls for measuring Gb effects on ISR markers. We euthanized the mice 4 or 24 hours after injection (two mice per genotype per time point). The time points were chosen as the half-life of Gb in blood/tissue is approximately 6 hours: Gb levels are relatively high at 4 hours after injection whereas at 24 hours after injection most of the Gb has been cleared. Organs were removed, snap frozen in liquid nitrogen and stored at −80° C. Tissue samples for RNA and protein analyses were prepared as described [36]. In postmortem brain tissue we measured levels of phosphorylated eIF2a with Western blot and levels of mRNAs encoding ATF4 and ATF4-regulated targets CHOP and TRIB3 with qPCR. Based on Gb's inhibitory effect on GADD34 we expected that Gb would increase eIF2a phosphorylation and ATF4 expression. Surprisingly, the results showed the opposite: in brain tissue of Gb-injected animals levels of eIF2a phosphorylation were lower than in saline-injected animals, irrespective of the mouse genotype (FIG. 10). This reduction was transient and only observed 4 hours after Gb injection. Levels of eIF2a phosphorylation were normalized 24 hours after injection. Only in 2b5ho mice the transient decrease in eIF2a phosphorylation correlated clearly with a transient decrease in Atf4 mRNA levels. The Atf4 mRNA expression level in brain tissue from wt mice appeared to be unaffected by Gb injection, possibly because this expression was very low or absent (compare also ATF4-driven expression of Trib3 mRNA in wt and 2b5ho mice). Alternatively, the lack of statistical significance is due to the low number of animals per group (n=2). Ddit3 and Trib3 mRNA expression was reduced at both time points in Gb-injected compared to saline-injected 2b5ho mice (although statistical significance was not reached for the Trib3 mRNA reduction at 4 hours). The discrepancy between Gb effects on eIF2a phosphorylation and Atf4 mRNA expression versus DdiI3 and Trib3 mRNA expression may be a matter of differences in turnover of phosphorylation eIF2a or investigated mRNAs (and is perhaps related to the dynamics of the ISR). Alternatively, Gb may not inhibit GADD34 and may target the ISR at a different site or in a different manner as reported [40].

Abbreviations

(57) EDTA=ethylenediaminetetraacetic acid eIF2B=eukaryotic translation initiation factor 2B DAPI=4′,6-diaminido-2-fenylindool GFAP=glial fibrillary acidic protein MBP=myelin basic protein MOG=myelin-oligodendrocyte glycoprotein p-eIF2=phosphorylated eukaryotic initiation factor 2 PBS=phosphate-buffered saline PFA=paraformaldehyde PLP=proteolipid protein RC2=radial glial cell marker 2 S100ß=Protein S100ß UPR=unfolded protein response VWM=Vanishing White Matter WMD=white matter disorder WT=wildtype

CITED ART

(58) 1 Bonkowsky J L, Nelson C, Kingston J L, Filloux F M, Mundorff M B, Srivastava R. The burden of inherited leukodystrophies in children. Neurol 2010; 75: 718-725 2 Vanderver A, Hussey H, Schmidt J L, Pastor W, Hoffman H J. Relative incidence of inherited white matter disorders in childhood to acquired pediatric demyelinating disorders. Semin Pediatr Neurol 2012; 19: 219-223 3 Gulati S, Jain P, Chakrabarty B, Kumar A, Gupta N, Kabra M. The spectrum of leukodystrophies in children: Experience at a tertiary care centre for North India. Ann Indian Acad Neurol 2016; 19: 332-338 4 van der Knaap M S, Pronk J C, Scheper G C. Vanishing white matter disease. Lancet Neurol 2006; 5: 413-423 5 Bugiani M, Boor I, Powers J M, Scheper G C, van der Knaap M S. Leukoencephalopathy with vanishing white matter: a review. J Neuropathol Exp Neurol 2010; 69: 987-996 6 Bugiani M, Boor I, van Kollenburg B, Postma N, Polder E, van Berkel C, van Kesteren R E, Windrem M S, Hol E M, Scheper G C, Goldman S A, van der Knaap M S. Defective glial maturation in vanishing white matter disease. J Neuropathol Exp Neurol 2011; 70: 69-82 7 Dooves S, Bugiani M, Postma N L, Polder E, Land N, Horan S T. van Deijk A L, van der Kreeke A, Jacobs G, Vuong C, Klooster J, Kamermans M, Wortel J, Loos M, Wisse L E, Scheper G C, Abbink T E, Heine V M, van der Knaap M S. Astrocytes are central in the pathomechanisms of vanishing white matter. J Clin Invest 2016; 126: 1512-1524 8 Leegwater P A, Vermeulen G, Könst A A, Naidu S, Mulders J, Visser A, Kersbergen P, Mobach D, Fonds D, van Berkel C G, Lemmers R J, Frants R R, Oudejans C B, Schutgens R B, Pronk J C, van der Knaap M S. Subunits of the translation intiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. Nat Genet 2001: 29; 383-388. 9 van der Knaap M S, Wolf N I, Heine V M. Leukodystrophies five new things. Neurol Clin Pract 2016; 6:1-9 10 Dooves S, van der Knaap M S, Heine V M. Stem cell therapy for white matter disorders: don't forget the microenvironment! J Inherit Metab Dis 2016; 39: 513-518 11 Goldman S A, Nedergaard M, Windrem M S. Glial progenitor cell-based treatment and modeling of neurological disease. Science 2012; 338: 491-495 12 Maeder M L, Gersbach C A. Genome-editing technologies for gene and cell therapy. Mol Ther 2016; 24: 430-446 13 Ricca A, Rufo N, Ungari S, Morena F, Martino S, Kulik W, Alberizzi V, Bolino A, Bianchi F, Del Carro U, Biffi A, Gritti A. Combined gene/cell therapies provide long-term and pervasive rescue of multiple pathological symptoms in a murine model of globoid cell leukodystrophy. Hum Mol Genet 2015: 24; 3372-3389 14 Bugiani M, Postma N, Polder E, Dieleman N, Scheffer P G, Sim F J, van der Knaap M S, Boor I. Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. Brain 2013; 136: 209-222 15 Tribouillard-Tanvier D, Béringue V, Desban N, Gug F, Bach S, Voisset C, Galons H, Laude H, Vilette D, Blondel M. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions. Plos One 2008; 3: e1981 16 Tsaytler P, Harding H P, Ron D, Bertolotti A. Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science 2011; 332:91-94 17 Wang L, Popko B, Tixier E, Roos R P. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis. Neurobiol Dis 2014; 71: 317-324 18 Ng S Y, Soh B S, Rodriguez-Muela N, Hendrickson D G, Price F, Rinn J L, Rubin L L. Genome-wide RNA-seq of human motor neurons implicates selective E R stress activation in spinal muscular atrophy. Cell Stem Cell 2015; 17: 569-584 19 Way S W, Podojil J R, Clayton B L, Zaremba A, Collins T L, Kunjamma R B, Robinson A P, Brugarolas P, Miller R H, Miller S D, Popko B. Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic. Nat Commun 2015; 6: 6532 20 Dash P K, Hylin M J, Hood K N, Orsi S A, Zhao J, Redell J B, Tsvetkov A S, Moore A N. Inhibition of eukaryotic initiation factor 2 alpha phosphatase reduces tissue damage and improves learning and memory after experimental traumatic brain injury. J Neurotrauma 2015; 32: 1608-1620 21 Vieira F G, Ping Q, Moreno A J, Kidd J D, Thompson K, Jiang B, et al. (2015) Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of AIS. PLoS ONE 10(8): e0135570. https://doi.org/10.1371/journal.pone.0135570 22 Saraswat Ohri S, Mullins A, Hetman M, Whittemore S R (2014) Inhibition of GADD34, the Stress-Inducible Regulatory Subunit of the Endoplasmic Reticulum Stress Response, Does Not Enhance Functional Recovery after Spinal Cord Injury. PLoS ONE 9(11): e109703. https://doi.org/10.1371/journal.pone.0109703 23 van der Voorn J P, van Kollenburg B, Bertrand G, van Haren K, Scheper G C, Powers J M, van der Knaap M S. Journal of Neuropathology & Experimental Neurology, Volume 64 2005, Pages 770-775. https://doi.org/10.1097/01.jnen.0000178446.41595.3a 24 Kapur M, Monaghan C E, and Ackerman S L, Regulation of mRNA Translation in Neurons—A Matter of Life and Death. Neuron Vol 96, 2017, Pages 616-637. https://doi.org/10.1016/j.neuron.2017.09.057 25 Heine V M, Rowitch D H. Hedgehog signaling has a protective effect in glucocorticoid-induced mouse neonatal brain injury through an 11 beta HSD2-dependent mechanism. J Clin Invest 2009; 119: 267-277 26 Rivero-Gutiérrez B, Anzola A, Martinez-Augustin O, de Medina F S. Stain-free detection as loading control alternative to Ponceau and housekeeping protein immunodetection in Western blotting. Anal Biochem 2014; 467: 1-3 27 Gürtler A, Kunz N, Gomolka M, Hornhardt S, Friedl A A, McDonald K, Kohn J E, Posch A. Stain-free technology as a normalization tool in Western blot analysis. Anal Biochem 2013; 433: 105-111 28 Buffo A, Rossi F. Origin, lineage and function of cerebellar glia. Prog Neurobiol 2013; 109: 42-63 29 Patro N, Naik A, Patro I K. Differential temporal expression of S100 beta in developing rat brain. Front Cell Neurosci 2015; 9: 87 30 Ajtai B M, Kálmán M. Glial fibrillary acidic protein expression but no glial demarcation follows the lesion in the molecular layer of the cerebellum. Brain Res 1998; 802: 285-288 31 Adorjan I, Bindics K, Galgoczy P, Kalman M. Phases of intermediate filament composition in Bergmann glia following cerebellar injury in adult rat. Exp Brain Res 2014; 232: 2095-2104 32 Lafarga M, Berciano M T, Saurez Andres M A, Berciano J. Reactive astroglia-neuron relationships in the human cerebellar cortex: a quantitative, morphological and immunocytochemical study in Creutzfeldt-Jakob disease. Int J Dev Neurosci 1993; 11: 199-213 33 Komine O, Nagaoka M, Watase K, Gutmann D H, Tanigaki K, Honjo T, Radtke F, Saito T, Chiba S, Tanaka K. The monolayer formation of Bergmann glial cells is regulated by Notch/RBP-J signaling. Dev Biol 2007: 311: 238-250 34 Wang X, Imura T, Sofroniew M V, Fushiki S. Loss of adenomatous polyposis coli in Bergmann glia disrupts their unique architecture and leads to cell nonautonomous neurodegeneration of cerebellar Purkinje neurons. Glia 2011: 59: 857-868 35 Das I, Krzyzosiak A, Schneider K, Wrabetz L, D'Antonio M, Barry N, Sigurdardottir A, Bertolotti A. Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit. Science 2015; 348: 239-242. 36 Wisse L E, Penning R, Zaal E A, et al., Proteomic and metabolomic analyses of vanishing white matter mouse astrocytes reveal deregulation of er functions, Front Cell Neurosci, 2017, 11. 37 Sekine Y, Zyryanova A, Crespillo-Casado A, et al., Stress responses. Mutations in a translation initiation factor identify the target of a memory-enhancing compound, Science, 2015, 348, 1027-30. 38 Sidrauski C, Tsai J C, Kampmann M, et al., Pharmacological dimerization and activation of the exchange factor eif2b antagonizes the integrated stress response, Elife, 2015, 4, e07314. 39 Dooves S B M, Wisse L E, Abbink T E M, van der Knaap M S, Heine V M., Bergmann glia translocation: A new disease marker for vanishing white matter identifies therapeutic effects of guanabenz treatment, Neuropathology and Applied Neurobiology, 2017, in press, doi: 10.1111/nan.12411. 40 Crespillo-Casado A, Chambers J E, Fischer P M, et al., Ppp1r15a-mediated dephosphorylation of eIF2a is unaffected by sephin1 or guanabenz, Elife, 2017, 6.